MedPath

Mannitol

Generic Name
Mannitol
Brand Names
Aridol, Bronchitol, Cystosol, Osmitrol, Sag-M
Drug Type
Small Molecule
Chemical Formula
C6H14O6
CAS Number
69-65-8
Unique Ingredient Identifier
3OWL53L36A

Overview

Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. Mannitol may also be used for the promotion of diuresis before irreversible renal failure becomes established; the promotion of urinary excretion of toxic substances; as an Antiglaucoma agent; and as a renal function diagnostic aid. On October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for this indication under the name BRONCHITOL® by Chiesi USA Inc.

Indication

Used for the promotion of diuresis before irreversible renal failure becomes established, the reduction of intracranial pressure, the treatment of cerebral edema, and the promotion of urinary excretion of toxic substances. Mannitol is also indicated as add-on maintenance therapy for improving pulmonary function in cystic fibrosis patients aged 18 and over who have passed the BRONCHITOL tolerance test (BTT). It is recommended that patients take an orally inhaled short-acting bronchodilator 5-15 minutes prior to every inhaled mannitol dose.

Associated Conditions

  • Acute Renal Failure (ARF)
  • Cystic Fibrosis (CF)
  • Edema of the cerebrum
  • Increased Intra Ocular Pressure (IOP)

Research Report

Published: Aug 3, 2025

An Expert Monograph on Mannitol: Chemistry, Pharmacology, and Clinical Applications

1. Drug Identification and Overview

1.1. Introduction to Mannitol

Mannitol is a small molecule drug, classified chemically as a six-carbon sugar alcohol, or polyol.[1] It is a versatile and critically important agent in modern medicine, primarily functioning as a potent osmotic diuretic.[3] Chemically, it is a hexahydric alcohol related to the sugar mannose and is a stereoisomer of sorbitol.[2] Its multifaceted utility spans a wide range of clinical scenarios. Therapeutically, it holds a vital role in emergency and critical care settings for the reduction of acutely elevated intracranial pressure (ICP) associated with cerebral edema and for lowering high intraocular pressure (IOP) in conditions like glaucoma.[1] It is also employed to promote diuresis in certain renal conditions, to facilitate the elimination of toxins, and as a diagnostic agent to measure kidney function.[1] In a distinct application, an inhaled formulation of Mannitol serves as an adjunctive therapy for managing the pulmonary symptoms of cystic fibrosis.[1]

Beyond its direct therapeutic roles, Mannitol is extensively utilized in the pharmaceutical and food industries. Its unique physicochemical properties, including chemical stability, non-hygroscopicity, and safety profile, make it a valuable pharmaceutical excipient in various dosage forms.[6] In the food sector, it functions as a low-calorie sweetener and texturizing agent.[4] The compound is identified by the DrugBank Accession Number DB00742 and the Chemical Abstracts Service (CAS) Registry Number 69-65-8.[1]

1.2. Chemical and Physical Profile

A thorough understanding of Mannitol's clinical and industrial applications begins with its fundamental chemical and physical characteristics.

Chemical Identity

Continue reading the full research report

Clinical Trials

View More Clinical Trials

Sign in to access the complete clinical trial database with detailed study information.

Title
Posted
Study ID
Phase
Status
Sponsor
2020/07/28
Phase 3
Completed
2020/06/11
Phase 2
Recruiting
2020/05/19
Phase 2
Completed
Raphael Heinzer
2020/05/12
Phase 2
Withdrawn
Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
2020/02/05
Phase 2
Completed
Phramongkutklao College of Medicine and Hospital
2020/01/03
Phase 3
Recruiting
dr. M.J.N.L. Benders
2019/12/05
N/A
Completed
Tribhuvan University Teaching Hospital, Institute Of Medicine.
2019/10/22
Phase 1
Active, not recruiting
Beijing Tiantan Hospital
2018/06/29
Phase 4
Completed
2018/04/23
Phase 3
Completed

FDA Drug Approvals

View More FDA Approvals

Sign in to access additional FDA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

View More EMA Approvals

Sign in to access additional EMA-approved drug information with detailed regulatory data.

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

View More HSA Approvals

Sign in to access additional HSA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

View More NMPA Approvals

Sign in to access additional NMPA-approved drug information with detailed regulatory data.

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

View More PPB Approvals

Sign in to access additional PPB-approved drug information with detailed regulatory data.

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

View More TGA Approvals

Sign in to access additional TGA-approved drug information with detailed regulatory data.

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

View More Health Canada Approvals

Sign in to access additional Health Canada approved drug information with detailed regulatory data.

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

View More CIMA AEMPS Approvals

Sign in to access additional CIMA AEMPS approved drug information with detailed regulatory data.

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

View More Philippines FDA Approvals

Sign in to access additional Philippines FDA approved drug information with detailed regulatory data.

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

View More Saudi SFDA Approvals

Sign in to access additional Saudi SFDA approved drug information with detailed regulatory data.

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

View More Malaysia NPRA Approvals

Sign in to access additional Malaysia NPRA approved drug information with detailed regulatory data.

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

View More UK EMC Drug Information

Sign in to access additional UK EMC drug information with detailed pharmaceutical data.

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.